At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
CAM2038drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Partially Randomized, 3 Treatment Groups, Multi-Site Study Assessing Pharmacokinetics After Administration of the Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) at Different Injection Sites in Opioid-Dependent Subjects With Chronic Pain
In Brief
A Phase 2 clinical trial evaluating CAM2038 for Opioid Use Disorder and Chronic Pain. Completed, enrolled 66 participants across 3 sites.
Detailed Summary
Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use Disorder, Chronic Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedMar 2016
Primary CompletionMay 2017
Study CompletionJul 2017
TodayJul 2026
First PostedMar 16, 2016
Enrollment StartFeb 1, 2015
Primary CompletionMay 17, 2017
Study CompletionJul 3, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.3 years ago
Interventions
CAM2038drug
Long-Acting Subcutaneous Injectable Depot of Buprenorphine